Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial

A health economic evaluation (HEE) is a comparative analysis of alternative courses of action in terms of both costs and consequences. A cost-effectiveness analysis is a type of HEE that compares an intervention to one or more alternatives by estimating how much it costs to gain an additional unit of health outcome. Cost-effectiveness analyses are commonly performed using Microsoft (MS) Excel. However, there is current interest in using other software that is better suited to more complex problems, methods, and data, as well as improved reproducibility and transparency. That is, it is increasingly important to be able to repeat an analysis of a particular data set and obtain the same results, and access the analysis and results in a clear and comprehensive openly available form. In this tutorial we provide a step-by-step guide on how to implement a mainstay model of HEE, namely a Markov model, in the statistical programming language R. The adoption of R for the purpose of cost-effectiveness analysis is highly dependent on the ability of the health economic modeller to understand, learn, and apply programming-type skills. R is likely to be less familiar than MS Excel for many modellers and so coding a cost-effectiveness model in R can be a large jump. We describe the technical details from the perspective of a MS Excel user to help bridge the gap between software and reduce the learning curve by providing for the first-time side-by-side comparisons of the Markov model example in MS Excel and R.

© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Similar articles

Naylor NR, Williams J, Green N, Lamrock F, Briggs A. Naylor NR, et al. Pharmacoeconomics. 2023 Jan;41(1):21-32. doi: 10.1007/s40273-022-01203-0. Epub 2022 Nov 28. Pharmacoeconomics. 2023. PMID: 36437359 Free PMC article.

Alarid-Escudero F, Krijkamp E, Enns EA, Yang A, Hunink MGM, Pechlivanoglou P, Jalal H. Alarid-Escudero F, et al. Med Decis Making. 2023 Jan;43(1):3-20. doi: 10.1177/0272989X221103163. Epub 2022 Jun 30. Med Decis Making. 2023. PMID: 35770931 Free PMC article.

Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, Sullivan W, Davison N, Saunders O, Sly I, Cain T, Lee D. Hart R, et al. Pharmacoeconomics. 2020 Jul;38(7):765-776. doi: 10.1007/s40273-020-00903-9. Pharmacoeconomics. 2020. PMID: 32236891

Hollman C, Paulden M, Pechlivanoglou P, McCabe C. Hollman C, et al. Pharmacoeconomics. 2017 Aug;35(8):817-830. doi: 10.1007/s40273-017-0510-8. Pharmacoeconomics. 2017. PMID: 28488257 Review.

Bidonde J, Fagerlund BC, Frønsdal KB, Lund UH, Robberstad B. Bidonde J, et al. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 21. Report from the Norwegian Institute of Public Health No. 2017-07. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Aug 21. Report from the Norwegian Institute of Public Health No. 2017-07. PMID: 29553668 Free Books & Documents. Review.

Cited by

Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I; MS Base Australian Researchers; Palmer AJ. Campbell JA, et al. Pharmacoeconomics. 2024 Aug 2. doi: 10.1007/s40273-024-01417-4. Online ahead of print. Pharmacoeconomics. 2024. PMID: 39095665

Milosavljević MN, Gutić M, Janjić V, Veselinović S, Djordjić M, Ivanović R, Milosavljević J, Janković SM. Milosavljević MN, et al. Open Med (Wars). 2024 May 21;19(1):20240970. doi: 10.1515/med-2024-0970. eCollection 2024. Open Med (Wars). 2024. PMID: 38799251 Free PMC article.

McManus E. McManus E. Pharmacoecon Open. 2024 Jul;8(4):569-583. doi: 10.1007/s41669-024-00487-6. Epub 2024 Apr 20. Pharmacoecon Open. 2024. PMID: 38643282 Free PMC article.

Marks Y, Hoch JS, Heath A, Pechlivanoglou P. Marks Y, et al. Pharmacoeconomics. 2024 Jul;42(7):783-795. doi: 10.1007/s40273-024-01374-y. Epub 2024 Apr 12. Pharmacoeconomics. 2024. PMID: 38607519

Lin YS, O'Mahony JF, van Rosmalen J. Lin YS, et al. Pharmacoecon Open. 2023 Jul;7(4):507-523. doi: 10.1007/s41669-023-00414-1. Epub 2023 Jun 1. Pharmacoecon Open. 2023. PMID: 37261616 Free PMC article.

References

    1. Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; 1997. (978-0198529453).
    1. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–21. - DOI
    1. Hart R, Burns D, Ramaekers B, et al. R and shiny for cost-effectiveness analyses: why and when? A hypothetical case study. Pharmacoeconomics. 2020;38:765–76. - DOI
    1. Edlin R, McCabe C, Hulme C, et al. Cost effectiveness modelling for health technology assessment, a practical course. Springer; 2015. https://doi.org/10.1007/978-3-319-15744-3 . - DOI
    1. Lunn DJ, Thomas A, Best N, et al. WinBUGS - A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–37. https://doi.org/10.1023/A:1008929526011 . - DOI